OMER Omeros Corporation

+0  (1%)
Previous Close 16.29
Open 16.47
Price To book 0.00
Market Cap 721.75M
Shares 43,822,000
Volume 298,585
Short Ratio 19.85
Av. Daily Volume 599,792

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2017.
IgA nephropathy
Phase 2 data released October 2016.
Kidney disorders
Approved June 2, 2014.
Cataract surgery
Phase 2 initiated Feb 2014. Trial was placed on hold due to preclinical concerns. To resume with with dosing limitations
Huntington disease
Phase 3 enrollment has opened - noted March 16, 2017.
Atypical hemolytic uremic syndrome (aHUS)

Latest News

  1. Biotech Movers: OncoMed, Incyte, Omeros
  2. 3 Biotech Stocks to Buy on Sale
  3. Omeros to Present at the Needham Healthcare Conference
  4. Biotech Premarket Movers: Halozyme, Omeros, Aralez
  5. Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases
  6. ETFs with exposure to Omeros Corp. : March 30, 2017
  7. Top Biotech Stocks for Growth Investors
  8. Osiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its OMR-721 Candidate Drug
  9. Here's Why Omeros Corporation Stock Climbed Higher Today
  10. 3 Stocks That Could Make You Rich
  11. Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation
  12. Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
  13. Omeros: Power in the Pipeline
  14. Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation
  15. Omeros Corp. :OMER-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  16. 3 Beaten-Up Biotech Stocks: Are They Bargains?
  17. Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : March 20, 2017
  18. Edited Transcript of OMER earnings conference call or presentation 16-Mar-17 8:30pm GMT
  19. Omeros reports 4Q loss
  20. Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results